No association of NAFLD-related polymorphisms in PNPLA3 and TM6SF2 with all-cause and cardiovascular mortality in an Austrian population study.
Cardiovascular risk
MAFLD
PNPLA3
TM6SF2
Journal
Wiener klinische Wochenschrift
ISSN: 1613-7671
Titre abrégé: Wien Klin Wochenschr
Pays: Austria
ID NLM: 21620870R
Informations de publication
Date de publication:
27 Apr 2023
27 Apr 2023
Historique:
received:
20
11
2022
accepted:
13
03
2023
medline:
27
4
2023
pubmed:
27
4
2023
entrez:
27
4
2023
Statut:
aheadofprint
Résumé
Single-nucleotide-polymorphisms in PNPLA3-rs738409 and the TM6SF2-rs58542926, associated with metabolic-dysfunction-associated fatty liver disease (MAFLD), have been discussed as potentially protective for cardiovascular diseases. Therefore, we aimed to study the associations of PNPLA3/TM6SF2 variants with MAFLD and cardiovascular risk in a population-based sample of asymptomatic patients. The study cohort comprised 1742 patients of European decent aged 45-80 years from a registry study undergoing screening colonoscopy for colorectal cancer between 2010 and 2014. SCORE2 and Framingham risk score calculated to assess cardiovascular risk. Data on survival were obtained from the national death registry RESULTS: Half of included patients were male (52%, 59 ± 10 years), 819 (47%) carried PNPLA3‑G and 278 (16%) TM6SF2-T-alleles. MAFLD (PNPLA3‑G-allele: 46% vs. 41%, p = 0.041; TM6SF2‑T-allele: 54% vs. 42%, p < 0.001) was more frequent in patients harbouring risk alleles with both showing independent associations with MAFLD on multivariable binary logistic regression analysis. While median Framingham risk score was lower in PNPLA3‑G-allele carriers (10 vs. 8, p = 0.011), SCORE2 and established cardiovascular diseases were similar across carriers vs. non-carriers of the respective risk-alleles. During a median follow-up of 9.1 years, neither PNPLA3‑G-allele nor TM6SF2‑T-allele was associated with overall nor with cardiovascular mortality. Carriage of PNPLA3/TM6SF2 risk alleles could not be identified as significant factor for all-cause or cardiovascular mortality in asymptomatic middle-aged individuals undergoing screening colonoscopy.
Sections du résumé
BACKGROUND AND AIMS
OBJECTIVE
Single-nucleotide-polymorphisms in PNPLA3-rs738409 and the TM6SF2-rs58542926, associated with metabolic-dysfunction-associated fatty liver disease (MAFLD), have been discussed as potentially protective for cardiovascular diseases. Therefore, we aimed to study the associations of PNPLA3/TM6SF2 variants with MAFLD and cardiovascular risk in a population-based sample of asymptomatic patients.
METHODS
METHODS
The study cohort comprised 1742 patients of European decent aged 45-80 years from a registry study undergoing screening colonoscopy for colorectal cancer between 2010 and 2014. SCORE2 and Framingham risk score calculated to assess cardiovascular risk. Data on survival were obtained from the national death registry RESULTS: Half of included patients were male (52%, 59 ± 10 years), 819 (47%) carried PNPLA3‑G and 278 (16%) TM6SF2-T-alleles. MAFLD (PNPLA3‑G-allele: 46% vs. 41%, p = 0.041; TM6SF2‑T-allele: 54% vs. 42%, p < 0.001) was more frequent in patients harbouring risk alleles with both showing independent associations with MAFLD on multivariable binary logistic regression analysis. While median Framingham risk score was lower in PNPLA3‑G-allele carriers (10 vs. 8, p = 0.011), SCORE2 and established cardiovascular diseases were similar across carriers vs. non-carriers of the respective risk-alleles. During a median follow-up of 9.1 years, neither PNPLA3‑G-allele nor TM6SF2‑T-allele was associated with overall nor with cardiovascular mortality.
CONCLUSION
CONCLUSIONS
Carriage of PNPLA3/TM6SF2 risk alleles could not be identified as significant factor for all-cause or cardiovascular mortality in asymptomatic middle-aged individuals undergoing screening colonoscopy.
Identifiants
pubmed: 37103556
doi: 10.1007/s00508-023-02196-2
pii: 10.1007/s00508-023-02196-2
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, part of Springer Nature.
Références
Jonas W, Schürmann A. Genetic and epigenetic factors determining NAFLD risk. Mol Metab. 2021;50:101111.
doi: 10.1016/j.molmet.2020.101111
pubmed: 33160101
Speliotes EK, et al. Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet. 2011;7(3):e1001324.
doi: 10.1371/journal.pgen.1001324
pubmed: 21423719
pmcid: 3053321
Balcar L, et al. PNPLA3 is the dominant SNP linked to liver disease severity at time of first referral to a tertiary center. Dig Liver Dis. 2022;54(1):84–90.
doi: 10.1016/j.dld.2021.06.015
pubmed: 34261618
Unalp-Arida A, Ruhl CE. Patatin-like phospholipase domain-containing protein 3 I148M and liver fat and fibrosis scores predict liver disease mortality in the U.S. population. Hepatology. 2020;71(3):820–34.
doi: 10.1002/hep.31032
pubmed: 31705824
Abul-Husn NS, et al. A protein-truncating HSD17B13 variant and protection from chronic liver disease. N Engl J Med. 2018;378(12):1096–106.
doi: 10.1056/NEJMoa1712191
pubmed: 29562163
pmcid: 6668033
Liu YL, et al. TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. Nat Commun. 2014;5:4309.
doi: 10.1038/ncomms5309
pubmed: 24978903
Mancina RM, et al. The MBOAT7-TMC4 variant rs641738 increases risk of nonalcoholic fatty liver disease in individuals of European descent. Gastroenterology. 2016;150(5):1219–1230e6.
doi: 10.1053/j.gastro.2016.01.032
pubmed: 26850495
Strnad P, et al. Heterozygous carriage of the alpha1-antitrypsin Pi*Z variant increases the risk to develop liver cirrhosis. Gut. 2019;68(6):1099–107.
doi: 10.1136/gutjnl-2018-316228
pubmed: 30068662
Holmen OL, et al. Systematic evaluation of coding variation identifies a candidate causal variant in TM6SF2 influencing total cholesterol and myocardial infarction risk. Nat Genet. 2014;46(4):345–51.
doi: 10.1038/ng.2926
pubmed: 24633158
pmcid: 4169222
Kahali B, et al. TM6SF2: catch-22 in the fight against nonalcoholic fatty liver disease and cardiovascular disease? Gastroenterology. 2015;148(4):679–84.
doi: 10.1053/j.gastro.2015.01.038
pubmed: 25639710
Dongiovanni P, et al. Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease. Hepatology. 2015;61(2):506–14.
doi: 10.1002/hep.27490
pubmed: 25251399
Liu DJ, et al. Exome-wide association study of plasma lipids in 〉300,000 individuals. Nat Genet. 2017;49(12):1758–66.
doi: 10.1038/ng.3977
pubmed: 29083408
pmcid: 5709146
Simons N, et al. PNPLA3, TM6SF2, and MBOAT7 genotypes and coronary artery disease. Gastroenterology. 2017;152(4):912–3.
doi: 10.1053/j.gastro.2016.12.020
pubmed: 28157516
Wernly S, et al. A sex-specific propensity-adjusted analysis of colonic adenoma detection rates in a screening cohort. Sci Rep. 2021;11(1):17785.
doi: 10.1038/s41598-021-97163-0
pubmed: 34493755
pmcid: 8423798
Semmler G, et al. Nut consumption and the prevalence and severity of non-alcoholic fatty liver disease. PLoS ONE. 2020;15(12):e244514.
doi: 10.1371/journal.pone.0244514
pubmed: 33382757
pmcid: 7774938
Eslam M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol. 2020; https://doi.org/10.1016/j.jhep.2020.03.039 .
doi: 10.1016/j.jhep.2020.03.039
pubmed: 32933781
Wilson PW, et al. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97(18):1837–47.
doi: 10.1161/01.CIR.97.18.1837
pubmed: 9603539
group, S.w., E.C.r. collaboration. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J. 2021;42(25):2439–54.
doi: 10.1093/eurheartj/ehab309
Kedenko L, et al. Genetic polymorphisms at SIRT1 and FOXO1 are associated with carotid atherosclerosis in the SAPHIR cohort. BMC Med Genet. 2014;15:112.
doi: 10.1186/s12881-014-0112-7
pubmed: 25273948
pmcid: 4411770
Rodriguez S, Gaunt TR, Day IN. Hardy-Weinberg equilibrium testing of biological ascertainment for Mendelian randomization studies. Am J Epidemiol. 2009;169(4):505–14.
doi: 10.1093/aje/kwn359
pubmed: 19126586
pmcid: 2640163
Krawczyk M, Liebe R, Lammert F. Toward genetic prediction of nonalcoholic fatty liver disease trajectories: PNPLA3 and beyond. Gastroenterology. 2020;158(7):1865–1880.e1.
doi: 10.1053/j.gastro.2020.01.053
pubmed: 32068025
Rüschenbaum S, et al. Patatin-like phospholipase domain containing 3 variants differentially impact metabolic traits in individuals at high risk for cardiovascular events. Hepatol Commun. 2018;2(7):798–806.
doi: 10.1002/hep4.1183
pubmed: 30027138
pmcid: 6049070
Wijarnpreecha K, et al. PNPLA3 gene polymorphism and overall and cardiovascular mortality in the United States. J Gastroenterol Hepatol. 2020;35(10):1789–94.
doi: 10.1111/jgh.15045
pubmed: 32220085
BasuRay S, et al. Accumulation of PNPLA3 on lipid droplets is the basis of associated hepatic steatosis. Proc Natl Acad Sci USA. 2019;116(19):9521–6.
doi: 10.1073/pnas.1901974116
pubmed: 31019090
pmcid: 6511016
Scorletti E, Carr RM. A new perspective on NAFLD: focusing on lipid droplets. J Hepatol. 2022;76(4):934–45.
doi: 10.1016/j.jhep.2021.11.009
pubmed: 34793866
Luo F, Oldoni F, Das A. TM6SF2: a novel genetic player in nonalcoholic fatty liver and cardiovascular disease. Hepatol Commun. 2022;6(3):448–60.
doi: 10.1002/hep4.1822
pubmed: 34532996
Pirola CJ, Sookoian S. The dual and opposite role of the TM6SF2-rs58542926 variant in protecting against cardiovascular disease and conferring risk for nonalcoholic fatty liver: A meta-analysis. Hepatology. 2015;62(6):1742–56.
doi: 10.1002/hep.28142
pubmed: 26331730
Stojkovic IA, et al. The PNPLA3 Ile148Met interacts with overweight and dietary intakes on fasting triglyceride levels. Genes Nutr. 2014;9(2):388–388.
doi: 10.1007/s12263-014-0388-4
pubmed: 24563329
pmcid: 3968290
Krarup NT, et al. The PNPLA3 rs738409 G‑allele associates with reduced fasting serum triglyceride and serum cholesterol in danes with impaired glucose regulation. PLoS ONE. 2012;7(7):e40376.
doi: 10.1371/journal.pone.0040376
pubmed: 22792295
pmcid: 3390392
Krawczyk M, et al. The common adiponutrin variant p.I148M does not confer gallstone risk but affects fasting glucose and triglyceride levels. J Physiol Pharmacol. 2011;62(3):369–75.
pubmed: 21893698
Kantartzis K, et al. Dissociation between fatty liver and insulin resistance in humans carrying a variant of the patatin-like phospholipase 3 gene. Diabetes. 2009;58(11):2616–23.
doi: 10.2337/db09-0279
pubmed: 19651814
pmcid: 2768178
Valenti L, et al. Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology. 2010;51(4):1209–17.
doi: 10.1002/hep.23622
pubmed: 20373368